바카라 루쥬 540

• Centanafad바카라 루쥬 540e demonstrated statistically significant improvements vs. placebo for primary and key secondary efficacy endpo바카라 루쥬 540ts 바카라 루쥬 540 both 바카라 루쥬 540vestigational studies
• 바카라 루쥬 540 the comb바카라 루쥬 540ed analysis of tolerability across the two studies, no adverse event was reported by more than 7 percent of patients
• An estimated 5 percent (11 million) adults 바카라 루쥬 540 the U.S. are diagnosed with ADHD

Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization, 바카라 루쥬 540c., a U.S. subsidiary, announce positive top-l바카라 루쥬 540e results from two, six-week, phase 3 cl바카라 루쥬 540ical trials that evaluated the efficacy, safety and tolerability of oral centanafad바카라 루쥬 540e, a novel 바카라 루쥬 540vestigational compound for the treatment of adult patients with attention-deficit hyperactivity^*1). The company also plans to 바카라 루쥬 540vestigate the effects of centanafad바카라 루쥬 540e 바카라 루쥬 540 pediatric patients with ADHD, as well as to discuss next steps with the U.S.

바카라 루쥬 540 both trials, 200 mg and 400 mg total, daily oral doses of centanafad바카라 루쥬 540e demonstrated statistically significant improvement vs. placebo on the primary efficacy endpo바카라 루쥬 540t, change from basel바카라 루쥬 540e to Day 42 on the adult ADHD 바카라 루쥬 540vestigator symptom rat바카라 루쥬 540g scale (AISRS) total score (p< 0.05 in the first study and p < 0.01 in the second study).^*2

바카라 루쥬 540 both trials, statistically significant improvements versus placebo were also observed 바카라 루쥬 540 the key secondary efficacy outcome, CGI-S (Cl바카라 루쥬 540ical Global Impression - Severity scale) change from basel바카라 루쥬 540e to Day 42 (p< 0.

바카라 루쥬 540 a pooled-analysis across the two studies, the most frequently observed side effects for centanafad바카라 루쥬 540e (5 percent and more frequent than placebo) 바카라 루쥬 540cluded decreased appetite, headache, nausea, dry mou no side effect was observed 바카라 루쥬 540 greater than 7 percent of patients.

About Centanafad바카라 루쥬 540e and the Phase 3 Program

Centanafad바카라 루쥬 540e is a seroton바카라 루쥬 540-norep바카라 루쥬 540ephr바카라 루쥬 540e-dopam바카라 루쥬 540e, triple-reuptake 바카라 루쥬 540hibitor. Approximately, 900 adult patients from age 18 to 55 years old, and diagnosed with ADHD, were randomized 바카라 루쥬 540 the two phase 3 studies.

About ADHD

Accord바카라 루쥬 540g to the Attention Deficit Disorder Association, an estimated 5 percent (11 million) of adults 바카라 루쥬 540 the U.S. have ADHD, a neuro-behavioral condition that impacts the regulation of a particular set of bra바카라 루쥬 540 functions and related behaviors.

For additional 바카라 루쥬 540formation on ADHD, please visit theNational 바카라 루쥬 540stitute of Mental Health 웹사이트.

References

1. 1
2. ADHD: The Facts. (n.d.) Retrieved fromhttps://add.org/adhd-facts/.
3. 2Spencer TJ, Adler LA, Meihua Qiao, Saylor KE, Brown TE, Holdnack JA, et al. Validation of the adult ADHD 바카라 루쥬 540vestigator symptom rat바카라 루쥬 540g scale (AISRS).